AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Here's Why Investors Should Buy Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit
by Zacks Equity Research
A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
DexCom (DXCM) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.
QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen
by Zacks Equity Research
QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances.
Illumina (ILMN), Nashville Biosciences Partner With Amgen
by Zacks Equity Research
Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.
Teladoc (TDOC) Boosts Revenue Guidance, Shares Jump 4.1%
by Zacks Equity Research
Teladoc (TDOC) expects around $1 billion in revenues from its BetterHelp mental health business in 2022.
Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind
by Zacks Equity Research
Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.
Abbott's (ABT) New Launch to Boost Blood Donation Experience
by Zacks Equity Research
Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub (SDC) on continued strategic partnerships and expansion in the teledentistry space.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
LabCorp (LH) Oncology Arm Gains Traction, Margin Pressure Stays
by Zacks Equity Research
In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
Baxter (BAX) Plans to Form Standalone Kidney Care Company
by Zacks Equity Research
Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Here's Why You Should Buy Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
UnitedHealth's (UNH) Optum to Boost Northern Light's Efficiency
by Zacks Equity Research
Per the deal, around 1,400 employees of Northern Light are likely to shift to UnitedHealth's (UNH) Optum this March.
Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.
Alcon (ALC) Gains From Innovation, Faces FX Challenges
by Zacks Equity Research
Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.
AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.
Here's Why You Should Retain Ecolab (ECL) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.